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Abstract
Solitary fibrous tumours of the pleura (SFTP) are rare neoplasms originating 
from one of the components of the sub-mesothelial connective layer underlying 
the pleura. They are the most common non-mesothelial primary pleural neo-
plasms but still remain relatively rare. Their behaviour is mostly indolent; how-
ever, some may de-differentiate into malignant and aggressive tumours. Surgical 
resection is the mainstay treatment for SFTP, even more so in case of voluminous 
masses, due to compression onto lung, mediastinum and great vessels. In this 
chapter, we discuss the disease characteristics reported in the literature with 
respect to clinical presentation, diagnosis and treatment; also, we will discuss the 
results of patients treated for SFTP who underwent a surgical treatment in our 
unit of thoracic surgery.
Keywords: solitary fibrous tumour of the pleura, pleura, surgery, resection, 
recurrence
1. Introduction
The pleura is composed of two sections: the mesothelium, a single layer of 
flattened cells, and a deeper sub-mesothelial layer formed by a matrix of collagen, 
elastic fibres, lymphatic and blood vessels.
Primary pleural tumours may originate from any of the pleural components.
Out of all the pleural neoplasms, 90% are malignant mesotheliomas, 5% are soli-
tary fibrous pleural tumours (SFPT) and the remaining 5% consists of less frequent 
variants (Table 1) [1].
Solitary fibrous tumours of the pleura originate from one of the components 
of the sub-mesothelial connective layer; therefore, its origin is mesenchymal. It 
usually presents as a well-circumscribed mass of occasional finding at chest X-rays 
performed for other reasons, since it presents asymptomatically.
SFTPs are the most common non-mesothelial primary pleural neoplasms, but 
still remain relatively rare. In fact, to date, <2000 cases have been reported in the 
literature [2]. They originate most frequently from the visceral pleura and have 
a benign course; only in a small percentage of cases (10–15%) their behaviour is 
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malignant, presenting a de-differentiated pattern, aggressive clinical behaviour 
(invasion of adjacent organs or cardiac compression due to its huge mass) and a 
trend to relapse after several years, therefore requiring long-term follow-up.
Although surgery is the main approach to treating SFTPs, local and distant 
recurrences may be observed after a complete resection [3, 4].
In this chapter we will discuss the characteristics of the disease reported in the 
literature with respect to its clinical presentation, diagnosis and treatment; also, 
we will present the results of patients who underwent surgery for SFTP in our 
Department from 1989 to 2019.
2. Historical background
Lieutaud was the first to report a tumour of pleural origin in 1767 but the first 
report of what was thought to be a SFTP dates back to 1870 in the work of Wagner [5].
In 1931, Klemper and Rabin [6] provided the first pathological distinction for 
pleural tumours classifying them into diffuse and localised mesotheliomas. They 
assumed a sub-mesothelial mesenchymal origin for the localised type.
Eleven years later, Stout and Murray [7] described the typical histological fea-
ture of the fibrous tumour of the pleura, the so-called patternless pattern, initially 
thought to be a vascular neoplasm related to smooth muscle perivascular cells 
(pericytes), therefore naming it hemangiopericytoma.
Since its pathological features were first described, the nomenclature has 
become confused, and the disease has also been referred to as localised mesothelio-
mas, localised fibrous tumours, fibrous mesotheliomas, or pleural fibromas.
The introduction of electron microscope and immunohistochemistry clarified 
the hypothesis that SFTP does not originate from the mesothelial layer but from the 
sub-mesothelial, undifferentiated mesenchymal layer [8, 9].
Benign
Solitary fibrous tumour of the pleura
Calcifying fibrous tumour
Adenomatoid tumour
Sclerosing pneumocytoma (hemangioma)
Pleural lipoma
Pleural Schwannoma
Malign
Solitary fibrous tumour of the pleura
Desmoplastic small round cell tumour
Localized malignant mesothelioma
Primary pleural thymomas
Synovial sarcoma of the pleura
Primary pleural liposarcoma
Fibrosarcomas of the pleura and desmoid tumours
Vascular origin
Epithelioid hemangioendothelioma
Angiosarcoma
Epithelioid angiosarcoma
Lymphatic
Primary pleural lymphoma
Table 1. 
Classification—rare pleural tumours.
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SFTP is now recognised as occurring anywhere in the body, including soft tissue 
and viscera, albeit with a peculiar predilection for body cavity sites, including 
pleura, peritoneum, and meninges.
In recent studies, SFTPs distribution is as follows: 30% in the thoracic cavity 
(pleura, lungs and mediastinum); 30% in the peritoneal cavity, in the retroperito-
neum or pelvis. When SFTP arise in the abdominal cavity it is mainly localised in 
the retroperitoneum followed by the pelvic soft tissue [10].
Nearly 20% of SFTPs are found in the head-neck district (including meninges). 
The remaining diseases develop in soft tissue of the trunk and extremities [11].
Data on presentation, clinical features and natural history of SFTPs are almost 
exclusively derived from retrospective series and case reports.
Since the discovery of SFTP, there has been some confusion in the classification 
by body site (pleural vs. extra-pleural), the histology (SFTP vs. hemangiopericy-
toma) and changes in diagnostic terminology has resulted in a fragmented and 
unsystematic approach to this uncommon neoplasm.
Robinson and Chmielecki’s [12, 13] recent discovery of a common driver 
mutation for pleural and extra-thoracic SFTPs in 2013 drastically changed our 
understanding of SFTP pathogenesis and led to new opportunities for diagnosis, 
characterisation and treatment.
2.1 Clinical features
Usually, the SFTP is discovered in asymptomatic middle-aged adults (occasion-
ally in children) and affects men and women equally. It is more common in the fifth 
and sixth decades of life. Some authors have reported that the tumour shows a slight 
predilection for women [2, 4, 14, 15].
It seems not to be associated with exposure to asbestos fibres exposure or 
tobacco smoke [16, 17].
Although the majority of SFTP are benign, it is reported that nearly 10–20% are 
malignant or show a malignant behaviour [18, 19].
Histologically, malignant tumours are classified according to England et al. [18] 
criteria:
• mitotic count with more than four mitosis/10 high power fields (HPF) (×400)
• presence of necrosis
• hyper cellularity as judged by nuclear crowding and overlapping
• presence of nuclear atypia
Mostly, patients are asymptomatic, but when they present symptoms, these usu-
ally include cough, chest pain, dyspnoea due to pleural effusion or the mass effect 
of the tumour. Haemoptysis and obstructive pneumonia may be observed as a result 
of airway obstruction. Chest pain has been reported more commonly with tumours 
arising from the parietal pleura.
A higher incidence of symptoms is also described in malignant variants [20], 
with a large variability of presentation varying from 43 to 73% [2, 14]; only 
few cases have been reported associated to paraneoplastic syndromes: 3% with 
hypertrophic pulmonary osteoarthropathy (HPO) and 2% with Doege-Potter 
syndrome [2].
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2.2 Paraneoplastic syndromes
2.2.1  Hypertrophic pulmonary osteoarthropathy or Pierre Marie-Bamberger 
syndrome
Hypertrophic pulmonary osteoarthropathy (HPO) describes a rheumatoid like 
disease of the bones and joints. The symptoms include clubbing of the fingers and 
toes, stiffness of the joints, oedema over the ankles and occasionally the hands, 
arthralgia, and pain along the surfaces of the long bones, especially the tibia [20].
Finger pressure on the surface of the tibia can elicit pain before the onset of any 
radiographic evidence of SFTP.
When clubbing and HPO are attributed to a paraneoplastic syndrome, this is 
referred to as the Pierre Marie-Bamberger syndrome since they first described the 
symptoms in 1890 [21, 22].
This is reported in up to 20% of patients and it is more commonly associated 
with large tumours (>7 cm) [20].
Some authors have reported that these clinical features usually resolve within 
2–5 months (or sometimes longer) after radical surgery and may reappear if the 
tumour relapses [3, 15, 18].
It is believed that local production of growth factors including PDGF and VEGF 
is implicated in the pathophysiology of HPO. In support of this, in a recent study 
the administration of zoledronate resulted in bone pain remission [23].
In another study, Hojo et al. suggested the abnormal production of hepatocyte 
growth factor as responsible for digital clubbing [24].
2.2.2 Hypoglycaemia (Doege-Potter syndrome)
The association between hypoglycaemia and a mesenchymal tumour has been 
reported for the first time in 1930 by Doege and Potter. This is present in <5% of 
patients affected by SFTP [25, 26].
Hypoglycaemia is equally distributed between benign and malignant SFTs albeit 
it occurs mostly in large peritoneal/pleural tumours [27].
Symptoms of hypoglycaemia include convulsions, syncope and coma and poten-
tially death resulting from severe hypoglycaemia, if not corrected promptly.
Hypoglycaemia seems to be caused by an excessive production and secretion of 
a partially processed, high molecular weight form of insulin-like growth factor 2 
(IGF-2) by the tumour [28]. The aberrant production of IGF-2 by the neoplasm is 
also the cause of refractory hypoglycaemia suppressing compensatory mechanism 
as gluconeogenesis in the liver and lipolysis in adipose tissue.
The paraneoplastic syndrome is generally cured after tumour’s resection, with 
the return to normal levels of insulin within a few days after the operation [29].
2.3 Radiographic features
2.3.1 Chest X-ray
Generally, SFTPs are an occasional finding in chest X-ray performed for other 
reasons.
They appear as a solid, sharply marginated, well-circumscribed solitary lesion 
originating from the periphery of the chest or from a lung fissure. It may grow to 
remarkable dimensions, at times occupying the entirety of the hemithorax. It is 
very difficult, if not impossible, to distinguish them from other masses of the lung 
by means of a plain chest X-ray (Figure 1).
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In particular, in neoplasms that reach a considerable size, areas of necrosis, 
haemorrhage and cystic or myxoid degeneration may be evident.
A pathognomonic radiological feature of pedunculated forms of SFTP originat-
ing from the visceral pleura is a change in shape and location of the mass during 
breathing or repositioning of the patient [30].
2.3.2 Computed tomography
At the computed tomography (CT) scan, SFTPs appear as a single lesion with 
well-defined margins arising from the chest wall (parietal pleura) or within a lung 
fissure (visceral pleura). They may grow up to reach remarkable dimensions, at 
times occupying the entire hemithorax and giving respiratory issues.
Distinctively, SFTP presents with its maximum diameter abutting the chest-
wall. The lesion usually forms right or acute angles with a smooth tapering margin 
with the chest-wall (Figure 2).
Tumours arising in an interlobar fissure may be more difficult to differentiate 
from an intraparenchymal mass since they are surrounded by lung parenchyma.
A pathognomonic finding in pedunculated lesions is the mobility of the tumour 
with changes in patient position. However, this data is conditioned by the size of 
the tumour: the larger the tumour, the less mobile it is due to the greater number of 
adhesions it contracts with the surrounding tissues. It is important to evaluate the 
relationships with the surrounding tissues as SFTP usually presents with well-
defined cleavage plans.
Another distinctive aspect of the fibrous tumour is its enhancement at the CT 
scan. Nearly 90% of lesions appear heterogeneous after administration of contrast, 
and in 75% of these a typical pattern may be recognised. Among these, the “geo-
graphic” one is the most represented. Small neoplasms tend to appear as sharp mar-
ginated masses with smooth margins, forming right or obtuse angles with the chest 
wall. Attenuation is homogeneous and similar to the adjacent musculature. This is a 
helpful feature to differentiate SFTPs from fatty lesions or saccular fluid collections. 
In regards to voluminous ones, they present as sharply marginated lesions with 
lobulated margins, creating acute angles with the chest wall. The contrast-enhanced 
CT evidences high attenuation of the mass due to its muscle fibres rich vascularisa-
tion, mainly and heterogeneous enhancement pattern (“geographic” the most 
common) with areas of necrosis, haemorrhages or cystic degeneration.
Absence of lymph nodal involvement and preservation of cleavage planes with 
adjacent structures provides evidence in support of the lesions’ benign nature. 
Figure 1. 
Chest X-ray lateral view of a large SFTP located in the right hemithorax.
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For this reason, the presence of regional lymphadenopathy is suggestive of an 
alternative diagnosis.
CT therefore proves to be a very reliable imaging exam, especially when inte-
grated with clinical and biopsy findings [30].
2.3.3 Magnetic resonance imaging
Magnetic resonance imaging (MRI) plays a limited role in the assessment of 
pleural disease. This exam proved to be superior to CT in studying the morphology 
and its relationship with the mediastinum, large vessels and diaphragm.
It is helpful in differentiating the tumour from other structures and in 
confirming intrathoracic localisation when the tumour abuts the diaphragm. 
Unfortunately, MRI patterns are quite variable in both benign and malignant 
SFTP [30].
2.3.4 F-18 fluoro-deoxy-glucose positron emission tomography
The role of F-18 fluoro-deoxy-glucose positron emission tomography 
(FDG-PET) in diagnosis of SFTP is limited and, to date, this exam is not able 
to discriminate between SFTP benign and malignant forms. However, it is 
reported its ability to identify areas of malignant transformation highlighting a 
focal increase of FDG uptake (SUVmax ≥ 3.0) within a large, otherwise benign 
appearing SFTP.
So, it would appear that PET scan could be useful to predict a clinically aggres-
sive behaviour of SFTP identifying areas of malignant histology within benign 
SFTP [31, 32].
Figure 2. 
Preoperative CT scan of a large SFTP in the right hemithorax.
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2.3.5 Ultrasounds
The role of ultrasound (US) in the diagnosis of SFTP is limited. These tumours, 
at US appear as homogeneous and hypoechoic masses, manifesting respiratory 
movement along-with the chest wall.
US could be useful to define the origin, thoracic vs. abdominal, of tumours 
which originate in close proximity with the diaphragm.
In conclusion, we can assume that it is difficult to differentiate between benign 
vs. malignant SFTPs based on specific radiological signs alone, albeit some radio-
logical features are more commonly associated with malignancy (large size, central 
necrosis and the presence of a pleural effusion).
It is important to underline the difficulty of making a diagnosis of certainty of 
SFTP with the sole aid of radiological imaging, for example, as described in a case 
report in which a giant ectopic pleural thymoma was pre-operatively diagnosed as 
an SFTP due to its radiological and clinical characteristics [33].
2.4 Pathologic characteristics
SFTP is an uncommon mesenchymal tumour, characterised by typical clinical 
presentation and variable biological behaviour.
It was first described arising from the pleura, but similar tumours can occur in 
the lung, in the mediastinum (in particular in the anterior one) and in other extra-
thoracic sites.
The distinctive macroscopic and histological features overlap with many other 
soft tissue tumours, so over the years it has been given different and very heteroge-
neous names such as benign mesothelioma, localised mesothelioma, solitary fibrous 
mesothelioma or the most famous name of hemangiopericytoma [7].
In the last decades, advances in histological, molecular and genetic research 
studies led to the discovery of more reliable methods of differentiating this tumour, 
bringing all these lesions together under the name of SFTP.
A preoperative diagnosis is usually preferable and obtained by means of a biopsy. In 
order to obtain as much tissue as possible for diagnosis, a radiologic guided core needle 
biopsy or an open incisional biopsy by an experienced surgeon is recommended [34].
2.4.1 Macroscopic description
The tumour mass is usually solitary but may also be multiple. Typically, it is well 
circumscribed, solid in appearance and greyish in colour, often pedunculate and 
with variable dimensions (often larger than 10 cm). Cystic, haemorrhagic, necrotic 
and calcified areas can be found.
2.4.2 Microscopic appearance
SFTP typically displays a uniform spindle cell morphology, variable cellularity—
without a specific growth pattern—a marked stromal hyalinisation and branching 
vascular pattern. The vascular pattern is characteristic and the vessels of different 
numbers and sizes are so-called “staghorn” and are very similar to those described 
for hemangiopericytoma [35].
The cells are characterised by having a tapered nucleus and a scarce and pale 
cytoplasm, the nuclear atypia is often minimal. Focally, a storiform or fascicular 
growth pattern could be present. The stroma could rarely be myxoid. Usually, <3 
mitoses can be counted for 2 mm2, and the count of four mitoses per 2 mm2 seems 
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to correlate with greater aggressiveness. Necrosis is infrequent, but when present is 
associated with poorer prognosis (Figure 3).
2.4.3 Immunophenotype
Most lesions are positive for CD34 antigens but nevertheless this positivity 
lacks specificity in a conclusive way. Also, CD99 and Bcl2 positivity are not specific 
and therefore of little help. The most specific marker (>95% of cases), recently 
described, is STAT-6 [36] and in particular its strong and widespread nuclear 
reactivity (Figure 4). Since some de-differentiated liposarcomas can also express 
STAT-6, they should be kept in mind into differential diagnosis [37].
Some cases may be positive for smooth muscle actin and others for EMA  
(epithelial membrane agent), pancytokeratin, S100 or desmin.
2.4.4 Differential diagnosis
SFTP should be differentiated from synovial sarcoma, sarcomatoid mesothe-
lioma, tumours of the nerve sheaths or type A Thymoma. The correct immunohis-
tochemical reactions are necessary for a correct classification.
Figure 4. 
Histologic features of SFTP. Immunohistochemical nuclear stain for STAT6 (IHC stain).
Figure 3. 
Histologic features of SFTP. Morphological appearance of SFTP: typical spindle cell proliferation with low 
cytologic atypia (haematoxylin-eosin stain).
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2.4.5 Genetic profile
SFTP harbours the gene fusion NAB2-STAT-6, which results from the intra-
chromosomal inversion inv(12)(q13q13), which causes the over-expression of the 
protein STAT-6, found through the use of the specific antibody for the immunohis-
tochemical reaction [12]. The over expression of IGF-2 found in some cases seems 
to be due to the loss of IGF-2 imprinting [38].
Telomerase reverse transcriptase (TERT) promoter mutations have been seen 
in 28% of SFT and are associated with high-risk pathologic characteristics and 
outcomes [39].
2.5 Diagnosis
The diagnosis of certainty of a SFTP is based on the histological examination of 
the specimen.
Usually, the first diagnostic step is a chest X-ray, performed for a different reason. 
The subsequent diagnostic procedure to further investigate the chest X-ray findings 
is a chest CT scan with contrast, which provides valuable information and orients the 
diagnosis towards a SFTP. As previously mentioned, this includes size and location 
of the tumour, the pleural origin or the presence of a stalk, areas of heterogeneity in 
larger lesions, an expression of the rich vascular network or intralesional haemorrhage 
or necrosis. These features also include the angle between the lesion and the thoracic 
wall which is useful when distinguishing between a pleural and a parenchymal lesion.
Larger tumours or tumours arising from the mediastinal pleura may be indistin-
guishable from mediastinal masses. In this case, the MRI scan is superior to the CT 
scan in studying the morphology and the relationship of the tumour with the medi-
astinum, large vessels and diaphragm. The MRI is also helpful in differentiating the 
tumour from other structures and better understanding margins and cleavages.
Fine needle aspiration biopsy (FNAB) is unreliable for providing a definitive 
diagnosis, which is mostly based on histological characteristics, as it provides insuf-
ficient tissue quantity [19], whereas a Tru-cut biopsy is more reliable. Weynand 
et al. reported a 100% diagnostic accuracy in determining a SFTP, using a transtho-
racic cutting needle [40].
2.6 Treatment
A complete surgical resection is the mainstay of the treatment of both benign 
and malignant SFTPs, the absence of neoplastic residual (R0) being the main 
prognostic factor [41].
Due to the anatomical localisation and involvement, an anatomical resection 
(lobectomy, bi-lobectomy or a pneumonectomy) is seldom necessary, since offers 
no advantages over wedge resections, for which a free margin on healthy tissue of at 
least 1–2 cm is recommended. In order to guarantee an adequate free margin from 
disease, a frozen section analysis is sometimes very useful [29]. SFTPs may occa-
sionally require a lobectomy or a pneumonectomy when the lesion is not peduncu-
lated but the base of implant is broad and sessile, or in case of an “inverted” tumour 
which grows inside the lung parenchyma.
When the tumour originates from the parietal pleura and adheres or invades the 
chest wall an extra-pleural dissection and a chest wall resection may be necessary [42].
Either a standard open thoracotomy or a video-assisted thoracic surgery (VATS) 
approach is valuable for the removal of an SFTP.
Diseases of Pleura
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The standard open approach (posterolateral/anterolateral thoracotomy) is 
mandatory for patients with large tumours, multiple synchronous lesions or with 
obvious malignant tumours, while the VATS approach is feasible in small (up to 
5.0 cm) lesions.
In case a VATS approach is preferred, it is necessary to avoid tumour dissemina-
tion using an endoscopic bag during the removal of the specimen, since contact 
metastases have been reported at the site of tumour extraction.
It is important to emphasise that the resection must be microscopically com-
plete, in order to prevent late recurrence. Relapse of a benign SFTP lesion may, in 
fact, result in the development of a more aggressive or malignant tumour [43].
The role of adjuvant therapy in SFTP is quite limited and has not really been 
explored, but occasional clinical series have been reported. Suter et al. [3] studied 
one alive patient with no recurrence for more than 20 years after subtotal resec-
tion of the tumour followed by radiotherapy, while, Veronesi et al. [44] report the 
significant reduction of a recurrent fibrous tumour, not eligible for surgery, after 
chemotherapy with Ifosfamide and Adriamycin.
2.7 Prognosis and survival
As reported in a review [45], the overall survival of patients affected by a benign 
pedunculated SFTP is close to 100%. The percentage is reduced to about 92% in 
case of benign sessile tumour and lower in case of malignant pedunculated (85%) 
and malignant sessile tumour (37%). In a multicentre study, a clinicopathological 
staging system was presented in order to predict the clinical course or recurrences 
[46] with the recurrence rate distributed as reported in (Table 2).
Boddaert et al. [47] in their meta-analysis including over 700 patients reported 
a higher recurrence rate in patients with malignant histology (England’s criteria), 
sessile morphology and incomplete resection.
Despite a recurrence after a total resection is an uncommon event, recurrences 
are also reported after many years, especially subsequently an incomplete resection 
or excision of a malignant sessile SFTP.
The most important prognostic factor seems to be a disease-free resection mar-
gin (R0); in support of this statement, Van Houdt and colleagues [46] in their series 
of 81 patients reported that a positive resection margin after surgery with curative 
intent, was correlated with local recurrence. They also reported that a high mitotic 
rate and tumour size >10 cm are correlated with the development of metastasis.
Recurrences may be fatal due to mediastinal invasion and superior vena cava 
obstruction.
In case of relapse, the primary attempt should be surgical excision, if technically 
and oncologically feasible, for both benign and malignant tumours.
Most recurrences occur within 24 months from surgery and are localised in 
the pleural cavity while distant metastasis seems to be a late event [45]. For these 
reasons a long-term follow-up, more than 15 years is recommended [45].
In conclusion, despite the fact that SFTPs are considered benign tumours, they 
may express an aggressive behaviour which leads the tumour to relapse.
Pathologically benign, pedunculated
Pathologically benign, sessile
Malignant pathology, pedunculated
Malignant pathology, sessile
Stage 0
Stage I
Stage II
Stage III
2% recurrence
8% recurrence
14% recurrence
63% recurrence
Table 2. 
De Perrot staging system.
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2.8 Our experience
2.8.1 Introduction
The University Unit of Thoracic Surgery of San Luigi Hospital deals with 
the diagnosis, treatment and follow-up of a wide range of diseases of the lung, 
trachea and bronchi, mediastinum and chest wall, with a specific commitment 
to oncological procedures by means of open and minimally invasive approaches 
(VATS).
Patients are referred to our Department from the outpatient clinic and through 
a multidisciplinary team meeting (MDT) held weekly. The present study describes 
a series of 64 consecutive cases, surgically treated at our Department during a 
30-year period.
2.8.2 Patients and methods
This is a single-centre retrospective analysis on prospectively collected data 
of patients operated on for a SFTP between December 1989 and March 2019 in 
our Unit of Thoracic Surgery. Data was retrieved form our surgical database and 
variables for each patient included: gender; age at operation; symptoms; smoking 
history; asbestos exposure; preoperative diagnosis; CT scan; PET scan (since 2003); 
bronchoscopy; preoperative diagnosis; tumour origin (visceral or parietal pleura) 
and side (right vs. left); tumour characteristics (implant on pleura—pedunculated 
vs. sessile—intrapulmonary growth; size); presence of associated paraneoplastic 
syndromes; comorbidities (Charlson Comorbidity Index); type of resection; 
postoperative complications; tumour histological characteristics (Ki67%; necrosis; 
mitotic count).
Surgical inclusion criteria included tumour resectability, no evidences of metas-
tases or other tumours, a good performance status (PS < 3). All patients underwent 
a CT scan and a preoperative bronchoscopy was performed in case of voluminous 
tumours. Preoperative diagnosis was attempted by means of a fine needle aspiration 
biopsy (FNAB) in all patients.
Postoperatively, all patients had a chest X-ray performed in post day one and 
after chest drain removal. Chest drains were removed when there was no air-leak 
detected and <250 ml of pleural fluid drained in 24/hour (Figure 5).
Patients’ follow-up was updated by contacting all those patients known to be 
alive at the time of their most recent outpatient clinic attendance. Information of 
patients lost at follow-up was retrieved through the General Register Office. The 
follow-up ended on the 1 March 2019.
2.8.3 Results
A total of 64 patients were operated on for a SFTP. Twenty-eight patients 
were males (43.7%) and 36 females (56.3%). Mean age at surgery was 61.7 years 
(range 35–83 years). Thirty-one (48.4%) patients were smokers or had a history of 
smoking.
Thirteen patients (20.3%) were symptomatic at diagnosis with predominant 
symptoms being cough and chest pain. No patients reported a history of asbestos 
exposure (Table 3).
All patients underwent chest X-rays and CT scans of the chest. Positron emission 
tomography was performed in 12 cases (18.8%).
Fifty tumours (78.1%) were based on the visceral pleura and 14 (21.9%) arose 
from the parietal pleura. Thirty-five tumours (54.9%) were pedunculated while 29 
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(45.3%) were broad based. Among tumours arising from visceral pleura, five (7.8%) 
showed a prevalent intrapulmonary growth (“inverted fibroma”).
The tumour was right-sided in 30 patients (46.8%) and left-side in 34 (53.2%). 
The lesions had a median diameter of 60 mm, the smallest tumour was 10 mm 
at maximum diameter and the largest was 380 mm (interquartile range: IQR-
40–130 mm) (Figure 6).
The Charlson comorbidity index (CCI) is reported for all patients in Table 3.
Local excision of the pleural tumour was accomplished in 57 patients (89%). In 
two (3.1%) cases a wedge resection was performed and in seven patients (10.9%) 
an anatomical resection was required (three lobectomies, one pneumonectomy and 
one segmentectomy).
Figure 5. 
Postoperative chest X-ray after radical excision of voluminous SFTP in the right hemithorax.
Age (mean, year) 61.7
Sex
Male
Female
28 (43.7%)
36 (56.3%)
Presenting symptoms
Cough
Chest pain
Fever
Dyspnoea
Weight loss
Hypoglycaemia
3
3
1
1
1
2
Smokers 31 (48.4%)
Charlson comorbidity index
CCI = 0
CCI = 1
CCI = 2
CCI = 3
CCI = 4
43
12
7
1
1
Table 3. 
Patient characteristics.
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Resection of the SFTP was performed through a thoracotomy in 51 cases 
(79.7%); VATS in nine cases (14.1%), and sternotomy in four cases (6.2%).
Histologically free margins were obtained in 63 cases (R0 residual disease). No 
patient was administered a neo-adjuvant or an adjuvant treatment.
Major postoperative complications included two atrial fibrillations, both treated 
with amiodarone, severe anaemia (two patients) with requirement of blood trans-
fusions, one acute respiratory failure. Minor complications included subcutaneous 
emphysema (one patient), persistent air-leak from the chest drain (one patient) and 
atelectasis (one patient).
The histological analysis of the tumours, including Ki67% and mitosis is 
reported in Table 4.
All patients were evaluated as part of postoperative and oncological follow-up 
with clinical examination and chest X-ray after one and 6 months. Chest CT scan 
was performed every year for the first 5 years after surgery. After the first 5 years, 
an annual chest X-ray was recommended, or at the discretion of the general practi-
tioner in the event of a new onset of symptoms. The annual examination is gener-
ally extended up to 15 years due to possible late onset of recurrences.
After a median follow-up of 135 months (IQR 49.2–198), 22 patients died 
(34.4%) and 42 are alive (65.6%). The mean disease-free interval (DFI) was 
28.9 months (range: 8.7–106.1 months). In eight patients (12.5%) a single recurrence 
was reported while, in one patient two consecutive recurrences were identified.
Figure 6. 
Surgical specimen after a radical excision of voluminous SFTPs located in the right hemithorax.
Ki67
>10%
<10%
8 (25%)
24 (75%)
N° mitosis × HPF
>10
<10
7 (20.6%)
27 (79.4%)
Necrosis
Present
Absent
6 (19.4%)
25 (80.6%)
Table 4. 
Histology.
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3. Conclusions
Solitary fibrous tumours of the pleura are rare pathological entities and are 
mostly discovered incidentally. Their behaviour is mostly indolent; however, some 
may de-dedifferentiate into malignant and aggressive tumours. Surgical resection 
is the mainstay treatment for SFTP, even more so in case of voluminous masses, due 
to compression onto lung, mediastinum and great vessels. Surgery should be carried 
out after a complete radiological assessment and a preoperative diagnostic attempt 
(FNAB), however, the diagnosis of certainty is obtained only with the definitive 
histological examination on surgical specimens. A long follow-up is recommended 
due to possible tumour recurrence.
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Appendices and nomenclature
SFTP solitary fibrous tumours of the pleura
HPO hypertrophic pulmonary osteoarthropathy
IGF-2 insulin-like growth factor 2
HPF high power fields
PDGF platelet-derived growth factor
VEGF vascular endothelial growth factor
CT computed tomography
MRI magnetic resonance imaging
FDG-PET F-18 fluoro-deoxy-glucose positron emission tomography
US ultrasounds
TERT telomerase reverse transcriptase
EMA epithelial membrane agent
FNAB fine needle aspiration biopsy
VATS video-assisted thoracic surgery
MDT multidisciplinary team meeting
CCI Charlson comorbidity index
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